Companies Akoya Biosciences
Akoya Biosciences (AKYA): executive pay, fiscal 2023
Free brief. Every figure links to the company’s own filing.
Akoya Biosciences no longer files a proxy statement; its last pay data is FY2023.
CEO pay, last three years
- $3,049,646FY2022
- $2,919,599FY2023
CEO total pay was $2,919,599 in fiscal 2023, down from $3,049,646 in fiscal 2022.
FY2023: salary $542,500 · bonus $0 · stock awards $984,000 · option awards $1,080,613
Full detail
Every table from the filing. Open any section.
Summary compensation table
| Named executive officer | Salary | Bonus | Stock awards | Option awards | Non-equity incentive | Pension / NQDC | All other | Total |
|---|---|---|---|---|---|---|---|---|
| Brian McKelligon | $542,500 | $0 | $984,000 | $1,080,613 | $307,125 | $0 | $5,361 | $2,919,599 |
| Chief Executive Officer | ||||||||
| Johnny Ek | 313,889 | 0 | 1,216,000 | 659,760 | 118,269 | 0 | 1,826 | 2,309,744 |
| Chief Financial Officer | ||||||||
| Frederic Pla | 414,167 | 0 | 360,000 | 270,153 | 156,375 | 0 | 10,690 | 1,211,385 |
| Chief Operating Officer | ||||||||
A dash means the company reported no figure in that column; 0 means it reported zero. Figures are as printed in the filing, without adjustment.
Three-year trend — total compensation per named executive
| Named executive officer | FY2023 total | FY2022 total | FY2021 total | Δ FY2022→2023 |
|---|---|---|---|---|
| Brian McKelligon | $2,919,599 | $3,049,646 | — | ↓ −130,047 |
| Johnny Ek | 2,309,744 | — | — | — |
| Frederic Pla | 1,211,385 | — | — | — |
Prior-year totals as disclosed in the corresponding proxy; deltas are computed values with the derivation shown in the register.
Incentive-plan design — the Compensation Discussion & Analysis
The company aims to provide competitive and fair compensation to directors and executive officers by assessing each element of compensation against a peer group to ensure alignment with market standards. Compensation is designed to motivate and reward the achievement of corporate and individual performance goals.
| CEO STI target (% of salary) | — |
|---|---|
| CEO LTI target (% of salary) | — |
| Independent consultant | Alpine Rewards |
| Clawback policy | true |
| Anti-hedging | true |
| Anti-pledging | true |
Equity grants and outstanding awards
Grants of plan-based awards — fiscal year 2023
| Executive | Award | Grant date | Threshold | Target | Granted | Maximum | Grant-date fair value |
|---|---|---|---|---|---|---|---|
| Johnny Ek | RSU | 2023-03-20 | — | — | 160,000 | — | — |
| Johnny Ek | OPTION | 2023-03-20 | — | — | 160,000 | — | 659,760 |
| Brian McKelligon | RSU | 2022-03-23 | — | — | 60,000 | — | — |
| Brian McKelligon | RSU | 2023-02-23 | — | — | 80,000 | — | — |
| Brian McKelligon | OPTION | 2023-02-23 | — | — | 160,000 | — | 1,080,613 |
| Frederic Pla | RSU | 2022-03-23 | — | — | 16,875 | — | — |
| Frederic Pla | RSU | 2023-02-23 | — | — | 20,000 | — | — |
| Frederic Pla | RSU | 2023-11-06 | — | — | 30,000 | — | — |
| Frederic Pla | OPTION | 2023-02-23 | — | — | 40,000 | — | 270,153 |
Vehicle mix — grant-date fair value by award type
| Named executive officer | Time-vested (RSU) | Performance-vested (PSU) | Options / SARs | % performance-vested |
|---|---|---|---|---|
| Johnny Ek | $0 | $0 | $659,760 | 0.0% |
| Brian McKelligon | 0 | 0 | 1,080,613 | 0.0% |
| Frederic Pla | 0 | 0 | 270,153 | 0.0% |
% performance-vested = PSU grant-date fair value ÷ (RSU + PSU + Options), a computed value with the derivation shown in the register.
Outstanding equity awards at fiscal year-end 2023
| Executive | Award | Shares unvested | Exercise price | Market value unvested |
|---|---|---|---|---|
| Frederic Pla | RSU | 16,875 | — | $82,350 |
| Frederic Pla | RSU | 20,000 | — | 97,600 |
| Frederic Pla | RSU | 30,000 | — | 146,400 |
| Brian McKelligon | RSU | 60,000 | — | 292,800 |
| Brian McKelligon | RSU | 80,000 | — | 390,400 |
| Johnny Ek | RSU | 160,000 | — | 780,800 |
Director compensation
No director compensation table is on file for fiscal year 2023.
Board fee structure and ownership guideline
| Annual cash retainer | $40,000 |
|---|---|
| Annual equity retainer | $170,000 |
| Per board meeting fee | — |
| Committee chair fees (audit / comp / nom-gov) | 20,000 / 15,000 / 10,000 |
| Stock ownership guideline | — |
Peer group, and who names Akoya Biosciences as a peer
Companies that benchmark against AKYA
3 companies name AKYA as a compensation peer
- 908 Devices Inc.MASSFY2025
- CODEXIS, INC.CDXSFY2024
- Ginkgo Bioworks Holdings, Inc.DNAFY2025
- Personalis, Inc.PSNLFY2025
Each company listed discloses AKYA in its own benchmarking peer group, as disclosed in each company's most recent proxy statement within the last two proxy seasons. Two companies are therefore absent by design: one that named AKYA in an earlier year and no longer does, and one whose own most recent disclosure is older than the last two seasons.
Chief executive pay against the peer group
Most recent fiscal-year chief executive compensation at each disclosed peer, taken from that company’s own proxy statement.
| Rank | Company | FY | Chief executive | Salary | Stock awards | Option awards | Non-equity incentive | Total |
|---|---|---|---|---|---|---|---|---|
| 1 | Akoya Biosciences | 2023 | Brian McKelligon | $542,500 | $984,000 | $1,080,613 | $307,125 | $2,919,599 |
Each peer’s compensation is from its most recently filed proxy; fiscal years differ by company. Each peer’s figures come from its own filings; the subject company is highlighted. Peers whose chief executive compensation is outside our coverage universe are stated as such, never left blank.
Say-on-pay history and pay ratio
No say-on-pay vote is on file for this company.
Insider trades since the proxy
No insider equity transactions reported since the proxy statement.
Sources (15 citations)
Each figure is listed with the filing it comes from, where it appears in that filing, and the value as printed. Any figure can be independently confirmed against the source.
- Section 01, Brian McKelligon. DEF 14A, filed 2024-04-23. Section “Executive Compensation”. As printed: 2,919,599. View filing ↗
- Section 01, Johnny Ek. DEF 14A, filed 2024-04-23. Section “Executive Compensation”. As printed: 2,309,744. View filing ↗
- Section 01, Frederic Pla. DEF 14A, filed 2024-04-23. Section “Executive Compensation”. As printed: 1,211,385. View filing ↗
- Section 03, Johnny Ek RSU. DEF 14A, filed 2024-04-23. Section “Executive Compensation” · grants of plan-based awards table. View filing ↗
- Section 03, Johnny Ek OPTION. DEF 14A, filed 2024-04-23. Section “Executive Compensation” · grants of plan-based awards table. View filing ↗
- Section 03, Brian McKelligon RSU. DEF 14A, filed 2024-04-23. Section “Executive Compensation” · grants of plan-based awards table. View filing ↗
- Section 03, Brian McKelligon RSU. DEF 14A, filed 2024-04-23. Section “Executive Compensation” · grants of plan-based awards table. View filing ↗
- Section 03, Brian McKelligon OPTION. DEF 14A, filed 2024-04-23. Section “Executive Compensation” · grants of plan-based awards table. View filing ↗
- Section 03, Frederic Pla RSU. DEF 14A, filed 2024-04-23. Section “Executive Compensation” · grants of plan-based awards table. View filing ↗
- Section 03, Frederic Pla RSU. DEF 14A, filed 2024-04-23. Section “Executive Compensation” · grants of plan-based awards table. View filing ↗
- Section 03, Frederic Pla RSU. DEF 14A, filed 2024-04-23. Section “Executive Compensation” · grants of plan-based awards table. View filing ↗
- Section 03, Frederic Pla OPTION. DEF 14A, filed 2024-04-23. Section “Executive Compensation” · grants of plan-based awards table. View filing ↗
- Section 01 trend, Δ column (computed). Computed. Δ = current-FY total − prior-FY total per named officer.
- Section 03b vehicle mix (computed). Computed. RSU / PSU / Options grant-date fair values summed per officer from the grants table; % performance-vested = PSU ÷ (RSU+PSU+Options).
- Akoya Biosciences (subject), Section 10b CEO total. DEF 14A, filed 2024-04-23. CEO total compensation as printed in Akoya Biosciences's own proxy. As printed: 2,919,599. View filing ↗